Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CABA-201

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Cabaletta Bio

Phase 2/3 Most advanced trial
CABA Developer
1 Registered trials

What is CABA-201?

CABA-201 (resecabtagene autoleucel) is an autologous T-cell preparation genetically modified to express a chimeric antigen receptor specific for CD19, with a 4-1BB costimulatory domain. It targets CD19-expressing B cells and is being studied in systemic sclerosis and interstitial lung disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rese-cel, Resecabtagene autoleucel
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
cytotoxic T-lymphocyte response
Therapy area
Dermatology, Respiratory
Developer
Cabaletta Bio (CABA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06328777 Phase 2/3 Systemic Sclerosis Recruiting CABA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Interstitial Lung DiseasesSclerodermaSystemic Sclerosis

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from Cabaletta Bio

DSG3-CAART Phase 1/2 MuSK-CAART Phase 1

Sources

Updated Oct 8, 2026. Something wrong or missing? Report it on the CABA page.

Follow CABA, the company behind CABA-201

See CABA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CABA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.